British private insurer AXA Health has said it will not pay for treatment with Novo Nordisk's weight-loss drug Wegovy, which launched in the U.K. on Monday.

AXA Health told Reuters in a statement: "As it stands, AXA Health would not cover the use of Wegovy as this would be prescribed as an outpatient drug for a chronic condition."

It declined to say how many people in the U.K. it insures, citing commercial sensitivity.